Skip to main content
Clinical Trials/NL-OMON46302
NL-OMON46302CompletedNot Applicable

Platelet reactivity, inflammation and endothelial dysfunction during and after exacerbation in chronic obstructive pulmonary disease (COPD) patients - IMPROVE study

Gelre Ziekenhuizen0 sites76 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
76

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • * Acute exacerbation of COPD, defined as an as an acute worsening of respiratory symptoms that results in additional therapy (COPD Gold 2018)
  • * >40 years oud
  • * Moderate to severe (>Gold 2) airflow limitation detected by spirometry (FEV1/FVC ratio < 70%, FEV1 < 80%) and clinical diagnosis of COPD confirmed by a pulmonologist.
  • * Current or former smoker, with *10 pack years of smoking

Exclusion Criteria

  • * Suspected or proven alternative diagnosis for the acute deterioration in symptoms such as pneumonia, pulmonary embolism or heart failure
  • * Use of anti-coagulants, aspirin or other platelet function inhibitors
  • * Use of statins or ACE inhibitors
  • * Concomitant diagnosis of asthma or other respiratory disease
  • * Diagnosis of hepatic and/or renal failure
  • * Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, systemic lupus erythematous (SLE), diabetes mellitus (DM)
  • * Malignancies (excluding basal cell carcinoma of the skin)

Investigators

Similar Trials

Platelet reactivity, inflammation and... | Clinical Trial